Form 4: Equillium Executive Chairman Acquires 50,000 Stock Options

Daniel Bradbury, Executive Chairman of Equillium, Inc., acquired 50,000 employee stock options on January 2, 2025, at an exercise price of $0.77 per share.

Summary

• Daniel Bradbury, the Executive Chairman of Equillium, Inc., has acquired 50,000 employee stock options.
• The transaction occurred on January 2, 2025.
• The exercise price for these options is $0.77 per share.
• The options vest over a period of four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by the Executive Chairman could be seen as a positive sign of confidence in the company's future performance.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, similar to practices at companies like Amgen, Gilead, and Regeneron.
• The vesting schedule of 25% after one year and the remainder over three years is also a typical vesting structure for stock options.

Stakeholder Impact

• The stock option grant could positively impact shareholder confidence by aligning executive interests with company performance.

Key Dates

Keywords

stock options, executive chairman, equity, vesting, Equillium, insider trading